drugset
drugset / Trial / NCT02595840

Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)

NCT02595840 ↗

Phase 2 Terminated 4 enrolled University of Duisburg-Essen
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy of afatinib maintenance with pemetrexed maintenance following induction therapy with platinum/ pemetrexed in patients with metastatic EGFR mutated non-small-cell lung cancer progressing after first-line treatment with afatinib as first tyrosine kinase inhibitor with respect to progression-free survival

Timeline

Start
2015-11-25
Primary completion
2017-11-20
Completion
2017-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Afatinib Small molecule 20 mg —
Subject Afatinib Small molecule 30 mg —
Subject Afatinib Small molecule 40 mg —
Subject Pemetrexed Small molecule 375 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

lung cancer